Literature DB >> 17517840

Measurement of voriconazole activity against Candida albicans, C. glabrata, and C. parapsilosis isolates using time-kill methods validated by high-performance liquid chromatography.

Yanjun Li1, M Hong Nguyen, Hartmut Derendorf, Shaoji Cheng, Cornelius J Clancy.   

Abstract

We developed a high-performance liquid chromatography (HPLC) assay to validate time-kill and postantifungal-effect (PAFE) experiments for voriconazole against Candida albicans, Candida glabrata, and Candida parapsilosis isolates. Voriconazole exerted prolonged fungistatic activity but no PAFE at concentrations achievable in human sera. HPLC confirmed that experiments were conducted at the desired steady-state voriconazole concentrations.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17517840      PMCID： PMC1932531          DOI： 10.1128/AAC.00308-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.

Authors:  Donna M MacCallum; Julie A Whyte; Frank C Odds
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

3.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments.

Authors:  Cornelius J Clancy; Hong Huang; Shaoji Cheng; Hartmut Derendorf; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

5.  Evaluation of voriconazole pharmacodynamics using time-kill methodology.

Authors:  M E Klepser; D Malone; R E Lewis; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

6.  Voriconazole therapeutic drug monitoring.

Authors:  J Smith; N Safdar; V Knasinski; W Simmons; S M Bhavnani; P G Ambrose; D Andes
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods.

Authors:  Erika J Ernst; Keiko Yodoi; Ellen E Roling; Michael E Klepser
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.

Authors:  Giovanni Di Bonaventura; Ilaria Spedicato; Carla Picciani; Domenico D'Antonio; Raffaele Piccolomini
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

9.  Organism-dependent fungicidal activities of azoles.

Authors:  E K Manavathu; J L Cutright; P H Chandrasekar
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 10.  In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.

Authors:  Ana Espinel-Ingroff
Journal:  Rev Iberoam Micol       Date:  2003-12       Impact factor: 1.044
View more
  5 in total

1.  A pharmacokinetic/pharmacodynamic mathematical model accurately describes the activity of voriconazole against Candida spp. in vitro.

Authors:  Yanjun Li; M Hong Nguyen; Shaoji Cheng; Stephan Schmidt; Li Zhong; Hartmut Derendorf; Cornelius J Clancy
Journal:  Int J Antimicrob Agents       Date:  2008-01-22       Impact factor: 5.283

2.  Effects of antifungal agents in sap activity of Candida albicans isolates.

Authors:  Carolina Rodrigues Costa; Rosália Santos Amorim Jesuíno; Janine de Aquino Lemos; Orionalda de Fátima Lisboa Fernandes; Lúcia Kioko Hasimoto e Souza; Xisto Sena Passos; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2009-08-15       Impact factor: 2.574

3.  Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates.

Authors:  Katherine T Nguyen; Philip Ta; Bich Thu Hoang; Shaoji Cheng; Binghua Hao; M Hong Nguyen; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

4.  Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species.

Authors:  Jeffrey B Locke; Amanda L Almaguer; Joanna L Donatelli; Ken F Bartizal
Journal:  Infect Dis Obstet Gynecol       Date:  2018-02-22

Review 5.  Postantifungal Effect of Antifungal Drugs against Candida: What Do We Know and How Can We Apply This Knowledge in the Clinical Setting?

Authors:  Nerea Jauregizar; Guillermo Quindós; Sandra Gil-Alonso; Elena Suárez; Elena Sevillano; Elena Eraso
Journal:  J Fungi (Basel)       Date:  2022-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.